Kintegral Advisory LLC Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Kintegral Advisory LLC cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 32.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,302 shares of the medical equipment provider's stock after selling 4,073 shares during the quarter. Kintegral Advisory LLC's holdings in Zimmer Biomet were worth $942,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Dodge & Cox lifted its position in shares of Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after buying an additional 2,044,645 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock valued at $1,559,147,000 after buying an additional 176,337 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after buying an additional 2,796,372 shares in the last quarter. Northern Trust Corp lifted its position in shares of Zimmer Biomet by 7.6% during the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock valued at $250,367,000 after buying an additional 167,435 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Zimmer Biomet during the 4th quarter valued at approximately $216,223,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 1.0%

Shares of ZBH traded up $0.89 during midday trading on Tuesday, reaching $93.46. The company had a trading volume of 1,502,714 shares, compared to its average volume of 1,811,538. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $116.71. The stock has a market cap of $18.49 billion, a PE ratio of 20.68, a price-to-earnings-growth ratio of 2.14 and a beta of 0.71. The firm has a 50 day simple moving average of $93.67 and a 200-day simple moving average of $101.57. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The company's revenue for the quarter was up 1.1% on a year-over-year basis. During the same period last year, the company earned $1.94 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's payout ratio is 21.24%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Robert W. Baird decreased their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Canaccord Genuity Group decreased their price objective on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a report on Monday, May 12th. JMP Securities decreased their price objective on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. decreased their price objective on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Zimmer Biomet has an average rating of "Hold" and a consensus price target of $110.56.

Insider Activity

In related news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider directly owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.70% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.